Abstract
Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and metastasis. Effective therapeutic agents for these cancers have not been established. Oncolytic viruses (OVs) constitute a novel class of promising, selective anticancer agents and recent studies have elucidated their unique features. Moreover, clinical trials are demonstrating promising results. Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for HCC in clinical trials. Few other OVs have entered clinical testing. Relatively few preclinical studies and clinical trials exist for biliary cancers. In this review, we introduce various approaches using OVs to treat the intractable hepatobiliary cancers.
Keywords: Gene therapy, gallbladder cancer, bile duct cancer, oncolytic virus, adenovirus, virotherapy.
Current Cancer Drug Targets
Title:Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
Volume: 18 Issue: 2
Author(s): Takeshi Yamada, Yukako Hamano, Naoyuki Hasegawa, Emiko Seo, Kuniaki Fukuda, Kazunari K. Yokoyama*, Ichinosuke Hyodo and Masato Abei*
Affiliation:
- Center for Stem Cell Research, Center for Infectious Diseases and Cancer Research, Graduate Institute of Medicine, Kaohsiung Medical University, 80708 Kaohsiung,Taiwan
- Division of Gastroenterology, Faculty of Medicne, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305- 8575,Japan
Keywords: Gene therapy, gallbladder cancer, bile duct cancer, oncolytic virus, adenovirus, virotherapy.
Abstract: Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and metastasis. Effective therapeutic agents for these cancers have not been established. Oncolytic viruses (OVs) constitute a novel class of promising, selective anticancer agents and recent studies have elucidated their unique features. Moreover, clinical trials are demonstrating promising results. Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for HCC in clinical trials. Few other OVs have entered clinical testing. Relatively few preclinical studies and clinical trials exist for biliary cancers. In this review, we introduce various approaches using OVs to treat the intractable hepatobiliary cancers.
Export Options
About this article
Cite this article as:
Yamada Takeshi , Hamano Yukako , Hasegawa Naoyuki , Seo Emiko , Fukuda Kuniaki , Yokoyama K. Kazunari*, Hyodo Ichinosuke and Abei Masato *, Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170330123841
DOI https://dx.doi.org/10.2174/1568009617666170330123841 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry 10 Years of SELDI: What Have we Learnt?
Current Proteomics From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Prognostic Significance of Hematopoietic-cell Serglycin for the Survival of Hepatocellular Carcinoma: A Single-center Retrospective Study
Combinatorial Chemistry & High Throughput Screening Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Analysis of Abdominal Computed Tomography Images for Automatic Liver Cancer Diagnosis Using Image Processing Algorithm
Current Medical Imaging Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry MGBG in Combined Anticancer Chemotherapy
Letters in Drug Design & Discovery Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis
Current Proteomics C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Selective Anti-proliferative Activity of Indole Alkaloids from Rhazya stricta Decne Leaves
Letters in Organic Chemistry CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry